TY - JOUR
T1 - Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes
T2 - A Randomized, Placebo-Controlled, Crossover Study
AU - Ranjan, Ajenthen
AU - Nørgaard, Kirsten
AU - Tetzschner, Rikke
AU - Steineck, Isabelle Isa Kristin
AU - Clausen, Trine Ryberg
AU - Holst, Jens Juul
AU - Madsbad, Sten
AU - Schmidt, Signe
N1 - © 2018 by the American Diabetes Association.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - OBJECTIVE This study investigated whether preceDing ethanol intake impairs glucose response to low-dose glucagon in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS This was a randomized, crossover, placebo-controlled study in 12 insulin pump-treated individuals (median [interquartile range] age, 37 [31-51] years; HbA1c, 57 [51-59] mmol/mol or 7.3% [6.8-7.5]; and BMI, 23.9 [22-25] kg/m2). During two overnight study visits, a 6 P.M. dinner (1 g carbohydrates/kg) was served with diet drink (placebo) or diet drink and ethanol (0.8 g/kg). After 8-9 h, ethanol was estimated to bemetabolized, and a subcutaneous (s.c.) insulin boluswas given to induce mild hypoglycemia. When plasma glucose (PG) was £3.9 mmol/L, 100 mg glucagon was given s.c., followed by another s.c. 100 mg glucagon 2 h later. Primary end point was incremental peak PG induced by the first glucagon bolus. RESULTS Ethanol was undetectable before insulin administration at both visits. The insulin doses (mean±SEM: 2.5±0.4 vs. 2.7±0.4 IU) to induce hypoglycemia (3.7±0.1 vs. 3.9 ± 0.1 mmol/L) did not differ and caused similar insulin levels (28.3 ± 4.± vs. 26.1 ± 4.0 mU/L) before glucagon administration on ethanol and placebo visits (all, P < 0.05). The first glucagon bolus tended to cause lower incremental peak PG (2.06 0.5 vs. 2.9 ± 0.3 mmol/L, P = 0.06), lower incremental area under the curve (87 ± 40 vs. 191 ± 37 mmol/L 3 min, P = 0.08), and lower 2-h PG level (3.6 ± 1.0 vs. 4.8 ± 0.4 mmol/L, P = 0.05) after ethanol compared with placebo. The second glucagon bolus had similar responses between visits, but PG remained 1.8 ± 0.7 mmol/L lower after ethanol compared with placebo. CONCLUSIONS The ability of low-dose glucagon to treatmild hypoglycemia persisted with preceDing ethanol intake, although it tended to be attenuated.
AB - OBJECTIVE This study investigated whether preceDing ethanol intake impairs glucose response to low-dose glucagon in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS This was a randomized, crossover, placebo-controlled study in 12 insulin pump-treated individuals (median [interquartile range] age, 37 [31-51] years; HbA1c, 57 [51-59] mmol/mol or 7.3% [6.8-7.5]; and BMI, 23.9 [22-25] kg/m2). During two overnight study visits, a 6 P.M. dinner (1 g carbohydrates/kg) was served with diet drink (placebo) or diet drink and ethanol (0.8 g/kg). After 8-9 h, ethanol was estimated to bemetabolized, and a subcutaneous (s.c.) insulin boluswas given to induce mild hypoglycemia. When plasma glucose (PG) was £3.9 mmol/L, 100 mg glucagon was given s.c., followed by another s.c. 100 mg glucagon 2 h later. Primary end point was incremental peak PG induced by the first glucagon bolus. RESULTS Ethanol was undetectable before insulin administration at both visits. The insulin doses (mean±SEM: 2.5±0.4 vs. 2.7±0.4 IU) to induce hypoglycemia (3.7±0.1 vs. 3.9 ± 0.1 mmol/L) did not differ and caused similar insulin levels (28.3 ± 4.± vs. 26.1 ± 4.0 mU/L) before glucagon administration on ethanol and placebo visits (all, P < 0.05). The first glucagon bolus tended to cause lower incremental peak PG (2.06 0.5 vs. 2.9 ± 0.3 mmol/L, P = 0.06), lower incremental area under the curve (87 ± 40 vs. 191 ± 37 mmol/L 3 min, P = 0.08), and lower 2-h PG level (3.6 ± 1.0 vs. 4.8 ± 0.4 mmol/L, P = 0.05) after ethanol compared with placebo. The second glucagon bolus had similar responses between visits, but PG remained 1.8 ± 0.7 mmol/L lower after ethanol compared with placebo. CONCLUSIONS The ability of low-dose glucagon to treatmild hypoglycemia persisted with preceDing ethanol intake, although it tended to be attenuated.
U2 - 10.2337/dc17-1458
DO - 10.2337/dc17-1458
M3 - Journal article
C2 - 29358493
SN - 0149-5992
VL - 41
SP - 797
EP - 806
JO - Diabetes Care
JF - Diabetes Care
IS - 4
ER -